A Two-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-7684 in Healthy Adult Volunteers
Study Details
Study Description
Brief Summary
This is a first in human study to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of ONO-7684 in healthy adult volunteers. This study will be conducted in 2 parts: Part A is a single-ascending dose and Part B is a multiple-ascending dose.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1 |
Detailed Description
This study aims to obtain safety, tolerability, pharmacokinetic and pharmacodynamic data when ONO-7684 is administered orally as single doses and as multiple doses to healthy subjects. The study will consist of 2 parts: A single ascending dose (SAD) phase (Part A); a multiple ascending dose (MAD) phase (Part B). One cohort of Part A will receive ONO-7684 under both fasted and fed conditions to investigate the effect of food.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: ONO-7684 Part A1 Single ascending doses of ONO-7684 or placebo orally under fasted conditions |
Drug: ONO-7684
Single ascending doses for cohorts A1-A8 and multiple ascending doses cohorts B1-3
|
Placebo Comparator: ONO-7684 Placebo Part A1 Single ascending doses of ONO-7684 or placebo orally under fasted conditions |
Drug: ONO-7684 Placebo
Placebo comparator
|
Experimental: ONO-7684 Part A2 Single doses of ONO-7684 or placebo orally under fed conditions |
Drug: ONO-7684
Single ascending doses for cohorts A1-A8 and multiple ascending doses cohorts B1-3
|
Placebo Comparator: ONO-7684 Placebo Part A2 Single doses of ONO-7684 or placebo orally under fed conditions |
Drug: ONO-7684 Placebo
Placebo comparator
|
Experimental: ONO-7684 Part B1 Eligible subjects will receive multiple doses of ONO-7684 or placebo orally |
Drug: ONO-7684
Single ascending doses for cohorts A1-A8 and multiple ascending doses cohorts B1-3
|
Placebo Comparator: ONO-7684 Placebo Part B1 Eligible subjects will receive multiple doses of ONO-7684 or placebo orally |
Drug: ONO-7684 Placebo
Placebo comparator
|
Outcome Measures
Primary Outcome Measures
- Number of participants with clinically significant changes in vital signs (Part A & B) [Part A: Day 1-4 & Follow-up and Part B: Day 1-15, 17 & Follow up]
Pulse rate (bpm), systolic and diastolic blood pressure (mmHg), Respiratory rate (bpm)
- Number of participants with clinically significant changes observed on 12-lead electrocardiogram (ECG) (Part A & B) [Part A: Day 1-4 & Follow up & Part B: Day 1,3,5,7,9,11,14,17 & Follow up]
Ventricular rate (beats/min), PR interval (msec), QRS interval (msec), QT (msec), QTcF interval (msec)
- Number of participants with clinically significant changes in cardiac telemetry (Part A only) [Part A: From 0.5-1 hours pre-dose until 12 hours after dosing at Day 1]
Number of participants with cardiac telemetry abnormalities will be reported.
- Number of participants with clinically significant changes in physical examination (Part A & B) [Part A: Day -1, 1-4 & Follow-up and Part B: Day-1, 1-17 & Follow up]
Number of participants with physical examination abnormalities will be reported.
- Number of participants with clinically significant changes in laboratory safety tests (haematology, biochemistry and urinalysis) (Part A & B) [Part A: Day-1, 1-4 & Follow up and Part B: Day-1, 1-17 & Follow up]
Number of participants with abnormalities in laboratory safety tests will be reported.
- Number of participants with adverse events (AE) (Part A & B) [Part A: Day-1, 1-4 & Follow up and Part B: Day-1, 1-17 & Follow up]
AE is any untoward medical occurrence in a subject or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Secondary Outcome Measures
- Pharmacokinetics (Cmax) [Part A: Day 1 through Day 4. Part B: Day 1 and Day 14]
Assessment of the maximum observed plasma concentration of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B
- Pharmacokinetics (tmax) [Part A: Day 1 through Day 4. Part B: Day 1 and Day 14]
Assessment of the maximum observed plasma concentration of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B
- Pharmacokinetics (AUClast) [Part A: Day 1 through Day 4. Part B: Day 14]
Assessment of the area under the curve of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B
- Pharmacokinetics (AUCinf) [Part A: Day 1 through Day 4. Part B: Day 14]
Assessment of the area under the curve of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B
- Pharmacokinetics (AUCt) [Part A: Day 1 through Day 4. Part B: Day 1]
Assessment of the area under the curve of concentration of ONO-7684 and 3-hydroxybenzoic acid - time from zero up to a definitive time, t in Parts A and B
- Pharmacokinetics (%AUCextrap) [Part A: Day 1 through Day 4. Part B: Day 14]
Assessment of the percentage of AUC∞ extrapolated from tlast to infinity of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B
- Pharmacokinetics (t1/2) [Part A: Day 1 through Day 4. Part B: Day 14]
Assessment of the elimination half-time of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B
- Pharmacokinetics (CL/F) [Day 1 through Day 4]
Assessment of the apparent clearance rate of ONO-7684 and 3-hydroxybenzoic acid in Part A only
- Pharmacokinetics (Terminal Rate Constant) [Day 1 through Day 4]
Assessment of the terminal rate constant (slowest rate constant of the disposition) of ONO-7684 and 3-hydroxybenzoic acid in plasma in Part A only
- Pharmacokinetics (Aet) [Day 1 through Day 4]
Assessment of the amount of ONO-7684 excreted in urine over the period of sample collection in Part A only
- Pharmacokinetic (fe/F) [Day 1 through Day 4]
Assessment of the fraction of orally administered ONO-7684 excreted into urine in Part A only
- Pharmacokinetic (CLr) [Day 1 through Day 4]
Assessment of the renal clearance of ONO-7684 from plasma in Part A only
- Pharmacokinetic (Ctrough) [Day 1 through Day 14]
Assessment of the trough plasma concentration of ONO-7684 and 3-hydroxybenzoic acid in Part B only
- Pharmacokinetic (AUCtau) [Day 14]
Assessment of the area under the plasma concentration of ONO-7684 and 3-hydroxybenzoic acid -time during a dosing interval in Part B only
- Pharmacokinetic (CLSS/F) [Day 14]
Assessment of total clearance of ONO-7684 from plasma after oral administration in Part B only
- Pharmacokinetic (VZ/F) [Day 14]
Assessment of apparent volume of distribution of ONO-7684 after non-intravenous administration calculated at steady state in Part B only
- Pharmacodynamic (change from baseline in aPTT activity) in serum [Part A: Day 1 through Day 4. Part B: Day 1 through Day 17]
Assessment of the effect of ONO-7684 in activated partial thromboplastin time in Parts A and B
- Pharmacodynamic (change from baseline in PT activity) in serum [Part A: Day 1 through Day 4. Part B: Day 1 through Day 17]
Assessment of the effect of ONO-7684 in prothrombin time in Parts A and B
- Pharmacodynamic (change from baseline in PT-INR activity) in serum [Part A: Day 1 through Day 4. Part B: Day 1 through Day 17]
Assessment of the effect of ONO-7684 in prothrombin time-international normalised ratio in Parts A and B
- Pharmacodynamic (change from baseline in FXIa activity) in serum [Part A: Day 1 through Day 4. Part B: Day 1 through Day 17]
Assessment of the effect of ONO-7684 in blood coagulation activated factor XI in Parts A and B
- Pharmacodynamic (correlation of aPTT and FXIa activity) in serum [Part A: Day 1 through Day 4. Part B: Day 1 through Day 17]
Assessment of the effect of ONO-7684 in the correlation of activated partial thromboplastin time to blood coagulation activated factor XI in Parts A and B
Eligibility Criteria
Criteria
Inclusion Criteria:
-
18-55 years
-
normotensive male volunteers, or female volunteers of non-childbearing potential (Part B only)
-
body mass index 18.0-30.0 kg/m2
-
deemed healthy on the basis of a clinical history, physical examination, ECG, vital signs, and laboratory tests of blood and urine
-
registered with a General Practitioner (GP) in the UK
-
agree to use an effective method of contraception
-
able to give fully informed written consent
Exclusion Criteria:
-
Positive tests for hepatitis B & C, HIV
-
severe adverse reaction to any drug
-
sensitivity to trial medication
-
drug or alcohol abuse
-
current smoker or use of nicotine containing products in the previous 6 months
-
vegetarians or vegans, or unwilling to eat a high-fat breakfast (Part A food effect cohorts only)
-
use of strong CYP3A4/5 or P-glycoprotein inhibitors or inducers, anticoagulants, antiplatelet agents, non-steroidal anti-inflammatory drugs and/or acetylsalicylic acid within the previous 30 days
-
prescription or over-the-counter medication, vitamins, herbal treatments or dietary supplements within the previous 7 days (with the exception of paracetamol [acetaminophen])
-
participation in other clinical trials of unlicensed medicines, or loss of more than 400 mL blood, within the previous 3 months or plan to donate blood or blood products in the 3 months after the trial
-
vital signs outside the acceptable range
-
clinically relevant abnormal findings at the screening assessment (including creatinine clearance, haemoglobin levels and QTcF)
-
acute or chronic illness
-
clinically relevant abnormal medical history or concurrent medical condition
-
objection by GP
-
possibility that volunteer will not cooperate
-
pre-menopausal females who are pregnant or lactating, or who are of childbearing potential
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Hammersmith Medicines Research (HMR) | London | United Kingdom | NW10 7EW |
Sponsors and Collaborators
- Ono Pharmaceutical Co. Ltd
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ONO-7684-01